Conscious Sedation for Cataract Operations Under Topical Anaesthesia
Launched by MENOUFIA UNIVERSITY · Apr 30, 2019
Trial Information
Current as of September 14, 2025
Completed
Keywords
ClinConnect Summary
In both groups, the patients will receive i.v. nalbuphine 50 μg/kg. Patients in group D, will receive an i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h. Patients in group P, will receive a bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion started at 0.025 mg/kg/min .If sedation score was \<3, rescue sedation with boluses of midazolam 0.01 mg/kg will be given. If the patient complained of pain (Numerical verbal pain rating scale ≥3) during the surgery, i.v. fentanyl 50 μg will be given as an intra-operative rescue analge...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Both genders,
- • 20 and 65 years,
- • American Society of Anesthesiologists (ASA) physical status I and II,
- • Scheduled for cataract extraction surgery under topical anaesthesia.
- Exclusion Criteria:
- • Known allergy to local anaesthetics,
- • Allergy to study drugs,
- • Second or third-degree heart block,
- • Alcohol or drug abuse
- • Morbid obesity, pregnant and lactating females,
- • Patients with severe cardiac, renal and hepatic disorders.
About Menoufia University
Menoufia University is a prominent educational and research institution located in Egypt, dedicated to advancing medical science and improving healthcare outcomes through innovative clinical research. The university's clinical trial sponsorship is characterized by a commitment to ethical standards, rigorous scientific methodology, and collaboration with multidisciplinary teams. By leveraging its academic resources and expertise, Menoufia University aims to contribute to the development of new therapies and interventions, ultimately enhancing patient care and public health within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, Shebin El Kom, Egypt
Patients applied
Trial Officials
Abd-Elazeem A Elbakry, MD
Principal Investigator
Associate professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials